NCT04341077

Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

A Phase 1, Open-Label, One-Center Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

Detailed description

This study will be a single-center, open-label, single dosing Fluzoparib study in healthy Chinese subjects to evaluate the pharmacokinetics and safety

Conditions

• Healthy Adult Male and Female Volunteers

Interventions

Type	Name	Description
DRUG	SHR3162	A single oral dose of fluzoparib on Day 1

Timeline

• Start date: 2020-04-10
• Primary completion: 2020-04-20
• Completion: 2020-10-20
• First posted: 2020-04-10
• Last updated: 2020-04-10